相关临床试验
142
78 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1954
进行中（未招募）
3
2.1%
已完成
36
25.4%
尚未招募
75
52.8%
招募中
23
16.2%
暂停
1
0.7%
Unknown
4
2.8%
暂无批准数据
- Median survival in high-grade glioma has improved from 9–12 months to 14–18 months, with nearly 40% of Grade-III and Grade-IV patients surviving beyond two years at some centers. - Molecular markers such as IDH1 mutations and MGMT status are guiding targeted therapies like Vorasidenib, moving treatment away from a one-size-fits-all approach. - Technologies including neuronavigation, fluorescent markers, and stereotactic radiosurgery are enabling more precise tumour removal while preserving healthy tissue. - Despite advances, delayed diagnosis remains a major challenge, with persistent headaches often dismissed as stress or migraine, and affordability barriers limit access to genomic profiling.
- Hospitals report significant success in treating multiple myeloma with advanced therapies, including second autologous stem cell transplants showing improved long-term survival rates. - A 77-year-old woman successfully underwent a second autologous stem cell transplant after relapsing seven years post-initial diagnosis, achieving complete remission despite her advanced age. - Treatment evolution includes replacement of conventional chemotherapy with targeted therapies, central role of daratumumab in induction regimens, and proven safety of second transplants when performed after three-year intervals. - Emerging treatments like CAR-T cell therapy and newer drugs including daratumumab, carfilzomib, and bispecific antibodies are achieving prolonged disease control in this complex blood cancer.
- India has developed its first indigenously discovered antibiotic, Nafithromycin, through collaboration between the Department of Biotechnology and Wockhardt pharmaceutical company. - The antibiotic demonstrates effectiveness against resistant respiratory infections, particularly benefiting cancer patients and individuals with poorly controlled diabetes. - India achieved a breakthrough in gene therapy with the first successful indigenous clinical trial for Hemophilia treatment, showing 60-70% correction rate with zero bleeding episodes. - The country has sequenced over 10,000 human genomes and aims to scale up to one million genomes as part of its national genomic mission.
